Pfizer Enters into Translational Research Collaboration with Adaptive Biotechnologies to Help Advance Novel Immuno-Oncology Solutions

Release Date:
Friday, January 8, 2016 8:00 am EST

Terms:
Dateline City:
NEW YORK & SEATTLE

NEW YORK & SEATTLE--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Adaptive Biotechnologies Corporation have entered into a translational research collaboration to leverage next generation sequencing of the adaptive immune system to advance Pfizer’s growing immuno-oncology franchise. Under the terms of the agreement, Pfizer and Adaptive will seek to combine drug development and platform technology biomarker expertise to identify patients who may preferentially benefit from immunotherapy.

Understanding and reliably measuring each patient’s immune response to their cancer before and after therapy is critical to defining the most appropriate immunotherapy for that patient. Adaptive's immunosequencing platform quantitatively and reproducibly measures the patient’s immune-cell repertoire, providing a powerful translational tool to accelerate Pfizer’s immuno-oncology biomarker and drug development programs.

"Immunotherapy is one of the most important advances in cancer therapy and offers the potential for long term disease control for many patients,” said Chris Boshoff, Vice President and Head of Early Development, Translational and Immuno-Oncology at Pfizer Oncology. “Pfizer is investing significantly in this space. The collaboration with Adaptive Biotechnologies supports our strategy of accelerating the development of potentially innovative new combination treatments by allowing us to develop a differentiated and competitive understanding of the immune landscape in specific tumor types.”

Adaptive Biotechnologies, the leading experts in profiling the immune cell repertoire, will work with Pfizer to apply their proprietary immunosequencing platform technology, bioinformatics capability, and scientific expertise to advance Pfizer’s rapidly expanding immuno-oncology pipeline.

“This collaboration with Pfizer is evidence of the immense impact immune repertoire profiling may have on the immuno-oncology space,” said Chad Robins, President, Chief Executive Officer and Co-Founder at Adaptive Biotechnologies. “Adaptive’s ability to precisely measure a patient’s immune response to cancer before and after treatment provides a universal tool that will help bolster our understanding of immuno-oncology approaches.”

About Adaptive Biotechnologies®

Adaptive Biotechnologies is the pioneer and leader in combining high-throughput sequencing and expert bioinformatics to profile T-cell and B-cell receptors. Adaptive is bringing the accuracy and sensitivity of its immunosequencing platform into laboratories around the world to drive groundbreaking research in cancer and other immune-mediated diseases. Adaptive translates immunosequencing discoveries into clinical diagnostics and therapeutic development to improve patient care.

Pfizer Inc.: Working together for a healthier world™

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world’s best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us.
PFIZER DISCLOSURE NOTICE

The information contained in this release is as of January 8, 2016. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about an agreement with Adaptive Biotechnologies Corporation (Adaptive) to leverage next generation sequencing of the adaptive immune system to help advance Pfizer’s growing immuno-oncology franchise and its potential benefits, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development; risks related to the ability to realize the anticipated benefits of the agreement with Adaptive, including the possibility that the expected benefits from such agreement will not be realized or will not be realized within the expected time period; other business effects, including the effects of industry, market, economic, political or regulatory conditions; and competitive developments.

A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2014, and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.

Language:
English
Contact:

Adaptive Biotechnologies
April Falcone
Mobile: 206-939-3835
media@adaptivebiotech.com

or

Pfizer Media:
Sally Beatty
Mobile: 347-330-7867
Sally.Beatty@pfizer.com

or

Pfizer Investor:
Ryan Crowe
Mobile: 215-260-0914
Ryan.Crowe@pfizer.com

Ticker Slug:
Ticker: PFE
Exchange: NYSE
ISIN: US7170811035